Phase 1 N=261 A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults
Respiratory Syncytial Virus (RSV)
Primary: Percentage of Participants With Solicited Symptoms — 35.9; 73.7; 60.0; 60.0 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=92 Optimizing Protein Intake in Older Americans With Mobility Limitations
Mobility Limitation
Primary: Change in Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DXA) — 0.14; 0.74; 4.43; 4.13 kg
Phase 2 N=40 Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Gastric Cancer · Esophageal Neoplasms
Primary: Objective Response (Complete, Partial, Stable and Progression) — 0; 7; 22; 9 participants
Phase 3 N=40 Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Primary: Percentage of Participants With H.Pylori Infection Eradication — 61 percentage of participants
N/A N=125 "Learning About Biologics"-Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: The Proportion of Subjects Who Are Classified as Having Made an Informed Value Concordant Choice at 2 Weeks — 32; 13 Percentage of subjects
Phase 1 N=40 An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions
Diabetes Mellitus, Type 2
Primary: Maximum Concentration (Cmax). — 90.883; 95.975; 1030.83; 986.93 ug/ml
N/A N=360 Participate While Pregnant Survey
Pregnancy
Primary: Willingness to Participate in Research While Pregnant — 319; 39; 288; 70 Participants
N/A N=27 Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women
Systemic Lupus Erythematosus
Primary: Anti-HPV 6 Seroconversion — 93.8 percentage of participants
N/A N=302 Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter
Atrial Flutter
Primary: Procedure-related Complication-free Rate — 92.7; 98.2 percentage of subjects
Phase 2 N=20 Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.
Acromegaly
Primary: Participants With Trough Human Growth Hormone < 2.5 ug/mL — 1; 8; 4; 6 participants with trough hGH < 2.5 µg/mL
Phase 2 N=8 The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics
Acromegaly
Primary: The Number of Patients Who Achieve a Trough Human Growth Hormone (hGH) Concentration of <2.5µg/L During the Last 12 Hours of the 23 Hour Profile Following Each Study…
Phase 2 N=113 Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction From Baseline in Eczema Area and Severity Index (EASI 50) at Week 12 — 48.2…
N/A N=50 Straumann Roxolid Multi-Center Study
Jaw, Edentulous, Partially
Primary: Mean Crestal Bone Level Change — 0.27; 0.48 mm — p=0.02
Phase 2 N=7 Bortezomib Plus Rituximab for EBV+ PTLD
Post-transplant Lymphoproliferative Disease · Solid Organ Transplant · Stem Cell Transplant (Bone Marrow Transplant)
Primary: Overall Response Rate — 3 Participants
Phase 2 N=37 PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)
Non-ischemic Dilated Cardiomyopathy
Primary: Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs) — 1; 0; 0; 1 Participants